Harvard Health Letter

New hope for people with migraine headaches

There are many different types of medicines that aim to prevent or reduce the frequency of migraine headaches. Now scientists are testing a new class of drugs to treat the condition. The drugs would block (inhibit) a brain protein called CGRP that sends pain messages to the body. Test results for two different CGRP inhibitors made news at the annual American Academy of Neurology meeting in April 2014. The drugs, called ALD403 and LY2951742, both reduced the time study participants experienced migraine headaches by about one day per month. The drugs are still in the testing phase and must be pitted against the older treatments to demonstrate their superiority. But so far, the results are promising.

To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »